SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
Yahoo Finance · Aug 27, 2026 · Sarepta Therapeutics Inc (SRPT)
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
Not investment advice. Cached headline, not a full reprint.